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As technology improves and experiences accumu-
late, the endovascular treatment of extracranial cere-
brovascular disease is gaining popularity and support-
ers. The widespread application of these techniques
has been limited by a significant incidence of periop-
erative neurologic complications ranging between
5.2% and 9.3%,1-4 including a stopped trial due to an
unacceptable high rate of neurologic events.5 The cri-
terion standard with which carotid artery angioplasty
and stenting (CAS) is compared is the result of con-
ventional carotid endarterectomy for symptomatic
patients (the North American Symptomatic Carotid
Endarterectomy Trial perioperative total neurologic
event rate of 5.8%)6 and is the result for asymptomatic
patients (the Asymptomatic Carotid Endarterectomy
Study perioperative total neurologic event rate of
2.65%).7 Despite improvements in the perioperative
stroke rates reported in many series of CAS in recent
years, it is obvious that for CAS to become an accept-
able alternative to conventional surgery for carotid
occlusive disease, significant improvements have to be
made to reduce procedure-related neuroembolism
and its associated neurologic sequelae.
Some strategies have been borrowed from the
experiences in coronary angioplasty and stenting, such
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as the perioperative use of antiplatelet drugs (eg, ticlo-
pidine, acetylsalicylic acid, clopidogrel, antiglycopro-
tein IIb/IIIa).8,9 Furthermore, the use of coronary-
type hydrophilic guidewires and coronary balloons for
predilatation when indicated and the use of stent
placement in all cases regardless of angioplasty
results10 are technical advances that have empirically
been adopted to prevent thromboembolic events.
Theron et al11 first introduced the idea of
endovascular cerebral protection in 1987. In recent
years, because of the increasing number of CAS pro-
cedures performed, this notion has gained popularity.
Several concepts for cerebral protection devices
have been approached and developed in an attempt
to reduce the chances of clinically significant neu-
roembolism. These include (1) cerebral protection
with balloon occlusion of the internal carotid artery
(ICA) (ie, PercuSurge), (2) cerebral protection with
balloon occlusion of the common carotid artery
(CCA) (Kachel’s technique), (3) cerebral protection
with filter-type devices placed in the ICA (ie,
Angioguard), (4) cerebral protection by inversion of
ICA blood flow achieved by balloon occlusion of the
CCA and external carotid artery (ECA) (Parodi tech-
nique) and (5) combinations of these techniques.
We have designed our own device (Parodi
Antiembolism System [PAES]) according to a new
concept that ensures cerebral protection by produc-
ing retrograde ICA flow at the time of lesion cross-
ing, angioplasty, and stent deployment achieved by
balloon occlusion of the CCA and the ECA.ICA
flow reversal is achieved with a carotid-to-femoral
arteriovenous shunt connecting the guiding catheter
to a femoral vein introducer. This shunt can be sup-
plemented with aspiration through the guiding
catheter, especially when the stent deployment
device is introduced.
Clinical data regarding the effectiveness of these
devices are small because most of them are current-
ly being tested. Theron et al12 reported on 138
angioplasties performed under cerebral protection
with his device (coaxial balloon catheter occluding
the ICA) with no embolization during angioplasty
and only two (1%) during or after stent placement.
The purpose of our study was to prospectively
analyze and compare the results of our early experi-
ence in CAS with or without cerebral protection with
respect to the incidence of perioperative neurologic
complications and mortality rate. We also evaluated
three different prototypes of cerebral protection
devices and analyzed their effectiveness, applicability,
and safety. This report includes the data on 46 con-
secutive patients treated in the last 12 months.
METHODS
Patients. Between September 1998 and
September 1999, 106 elective carotid revasculariza-
tion procedures were performed at the Instituto
Cardiovascular Buenos Aires. Of those, 46 (43.4%)
were performed with transfemoral angioplasty and
stenting by a single surgeon. All patients had preop-
erative bilateral duplex scan examination of the
carotid arteries, and those detected with an ICA or
bifurcation stenosis > 70% with symptoms and con-
sidered to be high-risk surgical candidates based on
the American Society for Anesthesia (ASA) criteria13
or because of a hostile neck (eg, reoperations, radia-
tion therapy) underwent CAS after obtaining
approval by the ethics committee. Asymptomatic
patients were selected to have carotid stenting
according to the following criteria: (1) stenosis ≥
80% by duplex scan examination and (2) stenosis
shown to be progressive in two consecutive studies.
Preoperative determination of the percentage
stenosis of the carotid arteries was based on peak sys-
tolic and end-diastolic velocities criteria obtained
from duplex scan examination. An ICA-CCA ratio
greater than 4 was considered a > 70% stenosis. A
peak systolic velocity more than 2.25 m/s defined a
stenosis of > 80%, and an end-diastolic velocity of >
1.25 m/s defined a stenosis of > 90%. Findings were
subsequently confirmed by intraoperative arteriogra-
phy in all cases.
Patients were excluded from CAS in case of (1)
an intracranial tumor or arteriovenous malforma-
tion, (2) peripheral vascular disease sufficiently
severe to prevent adequate vascular access, (3) severe
disability due to previous stroke or dementia, or (4)
an inability to give informed consent. Cerebral pro-
tection devices were used in 25 of these patients on
the basis of the availability of these devices.
Carotid stenting protocol. All patients took
aspirin, 325 mg/d, at least 7 days before the proce-
dure and ticlopidine (250 mg twice per day) or
clopidogrel (75 mg/d) starting 2 days before the
procedure. Heparin, given as an intra-arterial bolus,
was titrated to maintain the activated clotting time
between 200 and 250 seconds. Procedures were
done with the patients under local anesthesia, and
neurologic status was monitored constantly.
Transcranial Doppler scan monitoring was per-
formed routinely in patients with adequate middle
cerebral artery windows. Contralateral femoral
venous access was gained, and a transvenous pace-
maker was immediately available. Atropine (0.5-1
mg) was given as required during balloon inflation.
Blood pressure was monitored throughout the pro-
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cedure and was modulated by the administration of
intravenous nitroglycerin as required.
Percutaneous access was gained through the
femoral artery. Selective catheterization of carotid
arteries was performed with standard techniques.
Angulated angiographic views were recorded to fully
display the stenosis; we used an OEC 9600 series
(OEC Medical Systems Inc, Salt Lake City, Utah)
portable C-Arm or an Integris 5000 (Integris-Phillips
Medical Systems, Eindhoven, The Netherlands) with
road mapping and digital subtraction capabilities. A
tapered guidewire (TAD-II; Mallinckrodt Inc, St
Louis, Mo) was advanced to the ECA, and appropri-
ately sized guiding catheters (Flexor, Cook Inc,
Bloomington, Ind; Super Arrow Flex, Arrow
International Inc, Reading, Pa; or Parodi’s guiding
catheter, Arteria, San Francisco Science, San
Francisco, Calif) were placed in the CCA just proxi-
mal to the segment to be treated. Quantitative carotid
angiography was performed to measure the vessel
diameter to facilitate the sizing of balloons and stents.
In patients without cerebral protection, stenoses
were then crossed with flexible coronary guidewires
(V-18 Control Wire; Boston Scientific Corp,
Watertown, Mass). If it was necessary, a coronary
balloon of low profile was used for predilation, after
which a self-expandable Easy Wallstent (Boston
Scientific Corp) was deployed across the stenosis.
Intrastent balloon angioplasty was then performed,
and completion arteriograms were obtained routine-
ly, including lateral and anteroposterial intracerebral
views. Fluoroscopic guidance was used in the
removal of catheters and wires. Patients were trans-
ferred to the intensive care unit, after which sheaths
were removed with a normal activated clotting time.
Cerebral protection protocol. Twenty-five
patients underwent CAS with one of several cerebral
protection devices available. The devices included
the following:
• Angioguard (Angioguard Inc, Plymouth, Minn): a
low-profile guidewire-based, filter-type device (4F)
that is placed in the distal ICA after crossing the
stenotic lesion. It captures and removes embolic
debris while maintaining distal perfusion. Six
patients were protected with this device (Fig 1).
• PercuSurge (PercuSurge Inc, Sunnyvale, Calif): a
low-profile (0.014 and 0.018 in) guidewire-
based, balloon-type device that occludes the dis-
tal ICA during angioplasty and stent deployment.
Flushing and aspiration before reestablishing
blood flow remove particles. Ten patients were
protected with this device (Fig 2).
• PAES (Arteria): there are two components: (1) a 7F
or 8F guiding catheter with an inverted pear-shaped
balloon at the tip for occlusion of the CCA through
which a (2) low-profile guidewire-based, balloon-
type device is used for occlusion of the ECA. The
guiding catheter lumen is then externally connect-
ed to a contralateral femoral vein introducer with an
interposed blood filter, which achieves inversion of
ICA blood flow. During angioplasty and stent
deployment, additional suction is used to capture
potential embolic debris. Nine patients were pro-
tected with this device (Fig 3).
Procedures. In 35 patients (76.1%), the indication
for treatment was primary atherosclerotic disease.
Seven patients were treated for carotid restenosis, five
of whom were in the unprotected group. One patient
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Fig 1. Schematic representation of the filter-type device (Angioguard) at the time of balloon predilata-
tion angioplasty (A). Macroscopic particles are easily appreciated on filter retrieval (B).
was treated for radiation-induced carotid stenosis and
belonged to the unprotected group. One patient had
a combined CAS/subclavian angioplasty, one patient
had combined proximal CCA and ICA angioplasty
and stenting, and one patient had a combined
CAS/coronary artery bypass graft operation. One
combined procedure was performed in a patient from
the group with cerebral protection, and two proce-
dures were performed in patients from the unprotect-
ed group. Three patients with contralateral internal
carotid occlusion and eight patients with contralateral
hemodynamically significant stenosis underwent CAS.
The distributions of procedural characteristics between
the protected and unprotected groups are described in
Table I.
Monitoring. Transcranial Doppler ultrasound
scan was used routinely in all patients. Ipsilateral mid-
dle cerebral artery velocity was measured with a trans-
cranial Doppler ultrasonographic probe (DWL,
Elektronische Systeme GmbH, Sipplingen, Germany)
positioned over the temporal window and held with a
head strap. This instrument includes emboli-detection
software (data saved for off-line analysis), and high-
intensity transcranial sounds criteria were used to dis-
tinguish artifact from embolus. No attempt was made
to differentiate between air and particulate emboli.
Middle cerebral artery velocity measurements were
also stored on computer disk. Complete neurologic
evaluation was performed on all patients by an experi-
enced neurologist from an independent institution
preoperatively and postoperatively.
Embolic particles. Material collected from filters
or blood withdrawn from aspirations during CAS was
sent to the pathology department for particle analy-
sis. Particles obtained from those patients in whom
cerebral protection was performed with either the
PercuSurge or the Angioguard device were analyzed
independently as part of two separate multicenter
studies. Results of these studies have been published
and are reprinted in the “Results” section. Particles
obtained from those patients protected with the
PAES were stained with a toluidine solution, and
black-and-white digitized images were obtained and
analyzed with an image analysis program (Optimas
Analysis Program, version 5.0; optimAS A6, Zurich,
Switzerland). Mean particle diameters and the fre-
quency were recorded for each sample.
Definitions. Significant neurologic complica-
tions were defined as follows:
• Transient ischemic attack (TIA): a new neurolog-
ic deficit that changed the National Institutes of
Health (NIH) stroke scale14 by one point and
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Fig 2. A, ICA guidewire-based balloon occlusion device (PercuSurge) shown with the apparatus used
for balloon inflation-deflation. B, Schematic representation of the balloon in place during carotid
angioplasty and stenting with blood flow redirected toward the ECA.
persisted for less than 24 hours and completely
resolved or returned to baseline.
• Category 1 minor stroke: a new neurologic deficit
that changed the NIH stroke scale by one point and
persisted for more than 24 hours but completely
resolved or returned to baseline within 1 week.
• Category 2 minor stroke: a new neurologic deficit
that either resolved completely or returned to
baseline within 30 days or that changed the NIH
stroke scale by two or three points. By definition,
both categories of minor strokes are nondisabling
neurologic events.
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Fig 3. Schematic sequence of the Parodi device. Placement of Parodi’s guiding catheter in the CCA
below the stenotic lesion (A). Inflation of the CCA balloon with forward ICA flow maintained based
on retrograde ECA flow (B). Inflation of ECA balloon with inversion of ICA flow through Parodi’s
guiding catheter, which is then externally connected with a blood-filtered line to a femoral vein intro-
ducer (C). The connection is made using a three-way valve allowing additional suction when needed.
Intraoperative arteriogram showing both CCA and ECA balloons inflated and contrast material
retained in the ICA before being cleared through the guiding catheter (D).
D
• Major stroke: a new neurologic deficit that per-
sisted after 30 days and that changed the NIH
stroke scale by four points or more.
Morphologic definitions:
• Eccentric lesion: angiographic appearance of the
stenotic lumen in the outer quarter diameter of
the apparent normal lumen.15
• Bifurcation lesion: the ECA originated within the
stenosis and was completely surrounded by signif-
icant stenotic portions of the lesion to be dilated.
• Lesion calcification: radiologic densities readily
seen within the apparent vascular wall of the
artery at the site of the stenosis.16
• Ulcerated lesion: plaque was classified as ulcerat-
ed if it fulfilled radiographic criteria of ulcer
niche, seen in profile as a crater from the lumen
into a stenotic plaque and (when visible) a double
density on face view.17
Anatomic and procedural definitions:
• Bilateral carotid disease: a 60% or more diameter
narrowing in the ICA, the CCA, or both on both
sides, or a 60% or more diameter narrowing in the
left ICA, the CCA, or both with a 60% or more
diameter narrowing of the innominate artery.
• Combined procedure: performance of CAS and
coronary angioplasty or bypass graft surgery or any
additional supra-aortic trunk endovascular proce-
dure (ie, subclavian angioplasty and stenting).
Data collection. For each patient, information
was collected and reported prospectively in the hos-
pital record; also, a computerized database was used.
Routine clinical and laboratory data were continu-
ously recorded during the hospitalization and follow-
up visits. The primary clinical end point to analyze
was the rate of perioperative central neurologic
events, death, or both within 30 days of the proce-
dure. Secondary end points included technical com-
plications or difficulties as well as a critical assessment
of each cerebral protection device tested. Procedures
were performed by a single surgeon, but clinical eval-
uations were carried out by the surgical team includ-
ing all surgical staff, the primary care physician, car-
diologists, and anesthesiologists at this institution.
Independent neurologic evaluations were obtained
for each patient. Preoperative ASA scores were
assigned and recorded for each patient by an anes-
thesiologist. Morphologic data were recorded
prospectively by reviewing the angiographic films and
carotid duplex ultrasound scan reports. Preoperative
duplex scan data were corroborated by intraoperative
arteriograms in all patients. The clinical and demo-
graphic variables analyzed were age, sex, presence of
symptoms in the last 90 days, presence of coronary
artery disease, lower extremity intermittent claudica-
tion, diabetes mellitus, hypertension, hypercholes-
terolemia, current or former smoking habit, bilateral
carotid disease, prior endarterectomy on same side,
and contralateral occlusion. The morphologic vari-
ables considered were site (right or left carotid arter-
ies), lesion location at bifurcation, lesion length and
presence of multiple stenosis, eccentricity, calcifica-
tion, plaque ulceration, lesion severity (percentage
stenosis calculated with preoperative duplex ultra-
sound scan corroborated by arteriograms), residual
stenosis, and residual irregularity. The procedural
variables considered were the use of prestenting
angioplasties and the performance of combined or
simultaneous procedures.
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Table I. Procedure characteristics separated by




characteristics protection protection P value
Technical success 100% 95.24% ns
Predilatation 68% 28.5% .03
Combined* 1 2 ns
Contralateral occlusion 1 3 ns
Contralateral significant 5 2 ns
stenosis (> 60%)
*CAS and coronary artery bypass graft or other endovascular pro-
cedure.
ns, Not significant.
Table II. CAS patient demographic characteristic,
risk factor distribution, and indication for surgery 
Groups
Risk With Without 
factors protection protection P value
N 25 21
Age (y) 68.7 69.8 ns
Male 60% 95.2% < .02
Dyslipidemias 68% 71.4% ns
Hypertension 92% 90.4% ns
Diabetes 20% 38.1% ns
CHD 24% 61.9% .02
Smoking* 60% 90.8% .02
Symptoms† 48% 28.5% ns
Indications
Primary 23 (92%) 15 (71.4%) ns
Restenosis 2 (8%) 5 (23.8%) ns
Radiation 0 1 (4.8%) ns
*Current and former smoking.
†Includes TIAs, amaurosis fugax, and stroke.
CHD, Coronary heart disease; ns, not significant.
Statistical analysis. For nonparametric data, the
Mann-Whitney rank sum test was used to analyze
the different variables, and for parametric data, the
Student t test was used. A P value less than .05 was
considered to be statistically significant.
RESULTS
Demographics. The mean age of the group who
underwent carotid stenting was 67 years with a range
between 52 and 86 years. Thirty-five patients were
men (76.1%), 19 (41.3%) had significant coronary
artery disease, 42 (91.3%) were hypertensive, 13
(28.26%) had diabetes mellitus, 31 (67.4%) had
hyperlipidemia, and 33 (71.7%) were smokers. The
mean ASA score was 2.93. CAS was performed in 28
(60.9%) asymptomatic and 18 (39.1%) symptomatic
patients, of which 12 had TIAs, 3 had amaurosis
fugax, and 5 had previous stroke. Two patients had
both amaurosis fugax and hemispheric symptoms
concomitantly. Seven patients had restenosis after
prior endarterectomy, and one patient had radiation-
induced carotid stenosis associated with radical neck
dissection. The risk factor distributions and the demo-
graphic data of the cerebral protection group versus
the nonprotection group are shown in Table II.
Plaque characteristics. Plaque ulceration was
noted in 40.9% of the patients with an average
plaque length of 1.32 cm and eccentricity in 43.2%
of the cases. The location of the plaque was in the
ICA alone in 60.8% and in the carotid bifurcation in
39.2% of the cases. Table III shows the distribution
of plaque characteristics between the protected and
unprotected groups.
Outcomes. On an intention to treat basis, the
overall procedural success of CAS in this group of
patients was 97.4%. Access problems due to very tor-
tuous and calcified symptomatic iliac arteries pre-
cluded the positioning of the guiding catheter in the
CCA in one patient. Adequate placement of a cere-
bral protection device was achieved in 100% of the
patients in the protection group. The overall periop-
erative neurologic deficit rate for the whole group
was 4.34%. Two patients in the unprotected group
had perioperative neurologic deficits after CAS
(9.53%) versus none in the protected group (0%).
One patient had dysarthria that completely resolved
24 hours after CAS (TIA), and the other patient had
contralateral upper extremity paresis with complete
resolution in 1 week (category 2 minor stroke). No
major strokes developed. No cranial nerve deficits
were noted. Thirty-day mortality was 0% for the
whole group. None of the patients with contralater-
al ICA significant disease or occlusion that had cere-
bral protection had neurologic symptoms during
CAS. None of the patients had a Q-wave myocardial
infarction within 30 days of the procedure.
Nonneurologic procedure-related complications
included one patient with a self-limiting pericardial
hematoma in the unprotected group and a brief
episode of asystole at the time of angioplasty in one
patient rescued with an intravenous pacemaker.
Transcranial Doppler findings. Adequate mid-
dle cerebral artery windows could be found in about
75% of the patients. Embolic signals were detected
during lesion crossing, predilatation, stent deploy-
ment, and angioplasty in most patients. In those
patients with ICA balloon cerebral protection
devices, there were embolic signals during lesion
crossing, during angioplasty (probably due to ECA
embolism), and when balloons were deflated at the
end of the intervention. During protection with the
Angioguard system, there were embolic signals
throughout the entire procedure (Fig 1). With the
use of the Parodi device during CCA occlusion, no
embolic signals were detected, whereas ICA flow
inversion was documented with intraoperative
duplex ultrasound scan and fluoroscopy.
Follow-up. Thirty day neurologic and duplex
surveillance ultrasound scans were available for all
patients. No evidence of permanent new neurologic
deficits was noted. Residual stenosis was document-
ed in two patients: one with approximately 60%
stenosis distal to the stent and the other with 70%
intrastent stenosis.
Filter pathology. Macroscopically visible parti-
cles were found in the blood samples that were aspi-
rated and captured in the filter. Microscopic analysis
showed a variety of particles including atheromatous
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Table III. Plaque angiographic and echosonographic
characteristics of the plaque
Groups
Angiographic With Without
characteristic protection protection P value*
Mean stenosis
70%-90% 50% 69.3% ns
> 90% 50% 30.7% ns
Length 1.54 cm 1.69 cm ns
Excentric 47.8% 38.1% ns
Ulcerated 39.1% 42.8% ns
Location
ICA 56% 52.9% ns
Carotid bifurcation 44% 46.9% ns
*No significant differences were noted between the two groups.
ns, Not significant.
debris, cholesterol crystals, necrotic cores, fibrotic
elements, thrombi, platelets, cellular cytoplasms, and
macrophage foam cells.
In 24 patients who were treated with the
PercuSurge Device, the mean diameter of the parti-
cles aspirated was 279 µm (maximum, 5157 µm),
and the average number of particles per patient was
406.18 In the cases in which the Angioguard system
was used, the average number of particles found per
patient was 174. Fifty-seven percent of the particles
measured between 201 and 400 µm (data offered by
the company). With the PAES device, the average
number of particles aspirated per patient was 462,
with a mean diameter of 252 µm (minimum 52 to
maximum 3120 µm).
DISCUSSION
CAS-related embolism remains the main limita-
tion to widespread use of these techniques as an
acceptable approach for the management of most
carotid artery occlusive disease. The currently
accepted perioperative neurologic event rate varies
between 5% and 10% in most centers where unpro-
tected CAS is performed. This is clearly not an
acceptable rate when compared with results of con-
ventional endarterectomy for low-risk surgical candi-
dates and is still very controversial for high-risk
patients. Since their recent conception, the use of
cerebral protection devices as an adjuvant technique
during CAS has created great expectation, but data
on their effectiveness are unavailable. 
The occurrence of neurologic events during CAS
seems to be directly proportional to particle size and
number of embolic events.19,20 It is intuitive then
that any technique that reduces the number or the
size of embolic particles should reduce the chances
of clinical neurologic deficits related to CAS. In our
experience a significant number of particles were
trapped in either the filters when they were removed
or blood filtrates obtained from aspirates during
ICA balloon applications or when the Parodi tech-
nique was used. This effective reduction of embolic
particles could explain the lack of neurologic com-
plications during protected CAS in our experiences.
The fact that the difference between the group
with cerebral protection and the unprotected group,
regarding neurologic complications, is not statisti-
cally significant does not allow us to make stronger
conclusions regarding the need of cerebral protec-
tion devices. We think this is most likely due to a rel-
ative low number of cases and the low incidence of
neurologic complications in the unprotected group.
There were potential confounders: despite simi-
lar ASA scores within the groups, there was a signif-
icantly greater percentage of smokers and coronary
heart disease patients in the unprotected group
(Table II). On the other hand, in the protected
group there were more symptomatic patients and a
higher number of primary atherosclerotic lesions,
which could be more likely to embolize when com-
pared with restenotic or radiation-induced lesions.21
The ideal protection device should be, as out-
lined by Henry and Amor,22 simple and easy to use,
quick and radiopaque, steerable, and as atraumatic as
possible, so that the lesion may be crossed to avoid
detaching plaque, which will lead to cerebral
embolization. Finally, it should effectively eliminate
particles and debris generated by the dilatation.
The three devices used met most of these goals.
There were some disadvantages found using these
devices that are described below.
For the filter-type device:
1. The stenotic lesion needs to be crossed to place the
filter in the distal ICA. This can generate embolic
particles with a potential risk for neurologic seque-
lae. (In our experience, 30.2% of the carotid
plaques have thrombus lining their lumen.23) This
is especially true for the Angioguard device because
it has a relatively high profile (4F).
2. There is a risk of potential detachment of particles
during retrieval of the filter, especially when it is
full of embolic material as it happened in one of
our cases in which the particles occluded the flow
through the filter. In an oral communication H.
Londero reported one patient who had a disabling
stroke after CAS using Angioguard because of dis-
lodgment of particles during retrieval.
3. Filter-type devices will allow cerebral emboliza-
tion of particles smaller than porous size of the
membrane with unknown clinical consequences.
For the ICA balloon device:
1. With this technique, blood flow is redirected
toward the ECA flushing particles into it with the
possibility of retinal and cerebral embolization
through large collaterals or even through connec-
tions between vertebral and occipital arteries.24,25
2. There is a risk of spasm and intimal distal ICA
lesions on balloon inflation. In an oral commu-
nication Max Amor reported two ICA dissec-
tions in 80 cases of CAS with PercuSurge.
3. As with the filter-type device, the stenotic lesion
needs to be crossed to place the balloon in the
distal ICA.
4. Embolization has been described in the moment
of balloon deflation.
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5. The potential drawback of using the ICA balloon
device (and also using the Parodi device) is the
intolerance of the patient to the occlusion of
flow of the ICA (or the CCA) when the con-
tralateral carotid artery is occluded or when
there are insufficient connections in the circle of
Willis. This problem is expected to happen in less
than 10% of the cases.26
We successfully achieved retrograde ICA flow
with the Parodi device by occluding both the CCA
and the ECA and creating an arteriovenous shunt
between Parodi’s guiding catheter and the contralat-
eral femoral vein (Fig 3). This technique allows cere-
bral protection before lesion crossing, avoiding the
chances of generating embolic particles and poten-
tial neurologic complications. Also, potential ECA
embolic complications are prevented with balloon
occlusion. In some cases, partial occlusion of the
ECA was only achieved with maintenance of blood
flow only through proximal branches (ie, superior
thyroid artery) with little embolic consequences.
In some cases, patients will not tolerate prolonged
occlusions of the CCA. This can be predicted in some
patients with preoperative intracerebral angiograms
showing the absence of an anterior or a posterior
communicating artery. In this situation, the proce-
dure should be terminated, and conventional open
procedure with placement of a carotid shunt before
endarterectomy should be done. A feasible endovas-
cular alternative is suggested: With the patient under
general anesthesia (pentobarbital), the balloon in the
CCA is rapidly inflated, negative pressure (suction) is
applied to reverse the ICA flow, and a filter-type
device is advanced through the lesion and opened in
the distal ICA. The balloon is then rapidly deflated
reestablishing forward blood flow trough the ICA.
Kachel27 and later Connors28 have proposed that
balloon occlusion of the CCA alone would suffice
for cerebral protection according to a predicted ces-
sation of ICA blood flow, an inversion of blood flow
from the ICA to the ECA, or both. In our experi-
ence with the Parodi device, the reversal of flow
from the ICA to the ECA after balloon occlusion of
the CCA and before balloon occlusion of the ECA
was only observed in one of nine patients with most
patients having forward ICA flow from the ECA. It
is clear to us from these findings that in contrast to
what Kachel and Connors propose, balloon occlu-
sion of the CCA alone is not enough for adequate
cerebral protection in all patients because the retro-
grade flow from the ECA would sweep particles into
the ICA in most cases.
A problem encountered with the Parodi device
was that a significant reduction of flow through the
Parodi’s guiding catheter was noted when the stent
deployment device was introduced into the guiding
catheter. This was due to an increment in flow resis-
tance and can be overcome by the addition of suc-
tion to prevent forward ICA flow.
Overall cerebral protection devices are relatively
simple to use and are effective in reducing the num-
ber of embolic particles during CAS. They add only
a small amount of time to the procedure but could
add significant new expenses. In the future, the
applicability of CAS may become a widely accepted
alternative to conventional carotid endarterectomy
thanks to cerebral protection devices.
CONCLUSIONS
Our experience shows that cerebral protection
devices appear to be safe and effective in eliminating
embolic particles during CAS. This could be trans-
lated into a lower rate of neurologic events and com-
plications. The PAES ensures retrograde ICA flow
during CAS in every case without diverting embolic
particles into the ECA circulation. Thus we think, at
least in theory, that it provides protection against
CAS-related neurologic events. Larger numbers of
CAS with cerebral protection are needed to confirm
our findings.
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